A Dose-finding, Pharmacokinetic, Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Trial Profile

A Dose-finding, Pharmacokinetic, Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2014

At a glance

  • Drugs F16 IL2 fusion protein (Primary) ; Doxorubicin
  • Indications Breast cancer; Solid tumours
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Philogen
  • Most Recent Events

    • 24 Feb 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrial.gov.
    • 12 Oct 2012 Planned End Date changed from 1 Oct 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 12 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top